Stock MVIR B MEDIVIR AB
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Medivir AB

Equities

MVIR B

SE0020181014

Market Closed - Nasdaq Stockholm
Other stock markets
 11:59:59 08/05/2024 BST 		5-day change 1st Jan Change
3.03 SEK +1.00% Intraday chart for Medivir AB -3.81% +6.32%
05-07 Medivir Aktiebolag Approves Board Appointments CI
04-30 Transcript : Medivir AB, Q1 2024 Earnings Call, Apr 30, 2024

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Medivir AB Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Medivir AB Provides Update from Positive Type C Meeting with the FDA; Preparations for Enhanced Phase 2b in HCC with Fostrox + Lenvima
CI
FDA Grants Medivir AB´S MIV-711 Rare Pediatric Disease Designation and Orphan Drug Designation for the Treatment of Legg-Calvé-Perthes Disease
CI
Medivir Presents Data That Strengthens the Fostrox/Lenvima Combination in Primary Liver Cancer At Easl Liver Cancer Summit
CI
Medivir AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Medivir AB Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Medivir Presents the First Clinical Data with Fostrox + Lenvima At the Asco GI Scientific Congress
CI
Medivir AB Announces Further Improved Clinical Benefit with Fostrox + Lenvima as Data from the Ongoing Phase 1B/2A Study in Advanced Hepatocellular Cancer
CI
Medivir AB Announces Data from Ongoing Phase 1B/2A Study in Advanced Hepatocellular Cancers
CI
Medivir, Lonza Sign Manufacturing Deal for Fostrox
MT
Medivir AB Agrees with Lonza to Manufacture a Fostrox GMP Campaign, to Be Tested in 2L HCC with Intent to Commercialize Via Accelerated Approval
CI
Rights Issue: 1 new share @ 2.65 SEK for 1 existing share
FA
Medivir AB Announces Updated Formulation of Fostrox Critical to Support Planned Study with Accelerated Approval Intent in Second Line HCC
CI
Medivir AB to Present Clinical Data at ASCO-GI with Fostrox + Lenvima in HCC and Shares Positive Response from Type D Meeting with FDA
CI
Medivir AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Medivir AB to Report New and Updated Data from Ongoing Phase 2a HCC Study as Part of Its Third Quarter Report on Friday
CI
Medivir AB Announces All Patients in the Ongoing Phase 2A Study in Advanced Hepatocellular Car Car Car Carcinoma Has Now Dosed At Least Two Treatment Cycle
CI
Medivir AB Reports Promising Interim Data, Including A First Complete Response in Phase 1B/2A Hcc Study with Fostrox in Combination with Lenvima
CI
Medivir AB Announces Patent Application for Fostrox Approval in China
CI
Medivir AB Completes the Dose Escalation Part (Phase 1B) of the 1B/2A Study in Hcc and Focus on the Combination of Fostrox and Lenvima
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MVIR B Stock
  4. News Medivir AB
  5. Highlights